Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 3/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202807 | 0.81 | HTR1A (0.35) | ALDH1A1LMNA | |
| SCHEMBL4826122 | 0.81 | LMNA (0.39) | ALDH1A1LMNA | |
| SCHEMBL4826118 | 0.81 | LMNA (0.39) | ALDH1A1LMNA | |
| SCHEMBL3465919 | 0.79 | ALDH1A1 (0.36) | ALDH1A1LMNA | |
| SCHEMBL3193461 | 0.79 | PPARG (0.39) | ALDH1A1LMNA | |
| SCHEMBL3465821 | 0.77 | LMNA (0.43) | ALDH1A1LMNA | |
| SCHEMBL18822865 | 0.75 | ALDH1A1 (0.43) | ALDH1A1LMNA | |
| SCHEMBL3209335 | 0.74 | HTR1A (0.34) | ALDH1A1LMNA | |
| SCHEMBL3208700 | 0.70 | MAOB (0.42) | LMNA | |
| SCHEMBL5543733 | 0.70 | PTGS1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254892-B1 | BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2254892-A1 | BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES | Global Alliance For Tb Drug Development (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7666864-B2 | Bicyclic nitroimidazole-substituted phenyl oxazolidinones | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090281088-A1 | BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009120789-A1 | BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281088-A1 | BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES | O60361, OXA1L, TBCD | MLYCD 251/4885HDAC3 265/4885HDAC4 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.